Attach to Form 990 or Form 990-EZ.
See separate instructions.| (i) Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 9 above or IRC section (see instructions)) | (iv) Is the organization in col. (i) listed in your governing document? | (v) Did you notify the organization in col. (i) of your support? | (vi) Is the organization in col. (i) organized in the U.S.? | (vii) Amount of monetary support | |||
|---|---|---|---|---|---|---|---|---|---|
| Yes | No | Yes | No | Yes | No | ||||
| Total | |||||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2008 | (b) 2009 | (c) 2010 | (d) 2011 | (e) 2012 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") .... | 127,995,868 | 134,999,587 | 174,658,160 | 159,779,664 | 118,656,952 | 716,090,231 |
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf....... | 0 | 0 | 0 | 0 | 0 | 0 |
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | 0 | 0 | 0 | 0 | 0 | 0 |
| 4 | Total. Add lines 1 through 3 | 127,995,868 | 134,999,587 | 174,658,160 | 159,779,664 | 118,656,952 | 716,090,231 |
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f).. | 422,210 | |||||
| 6 | Public support. Subtract line 5 from line 4. | 715,668,021 | |||||
Calendar year
(or fiscal year beginning in) ![]() |
(a) 2008 | (b) 2009 | (c) 2010 | (d) 2011 | (e) 2012 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | 127,995,868 | 134,999,587 | 174,658,160 | 159,779,664 | 118,656,952 | 716,090,231 |
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | 6,957,976 | 3,548,746 | 3,812,083 | 4,528,150 | 4,810,808 | 23,657,763 |
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | 0 | 0 | 0 | 0 | 0 | 0 |
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part IV.).. | 71,369 | 2,589,864 | 84,038 | 378,313 | 351,342 | 3,474,926 |
| 11 | Total support (Add lines 7 through 10). | 743,222,920 | |||||






Calendar year (or fiscal year beginning in) ![]() |
(a) 2008 | (b) 2009 | (c) 2010 | (d) 2011 | (e) 2012 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | ||||||
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose...... | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513.. | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | ||||||
| 6 | Total. Add lines 1 through 5. | ||||||
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons... | ||||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
| c | Add lines 7a and 7b.. | ||||||
| 8 | Public support (Subtract line 7c from line 6.) | ||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2008 | (b) 2009 | (c) 2010 | (d) 2011 | (e) 2012 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | ||||||
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | ||||||
| 11 | Net income from unrelated business activities not included in line 10b, whether or not the business is regularly carried on. | ||||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part IV.) .. | ||||||
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | ||||||




| Facts And Circumstances Test |
|---|
| Explanation |
|---|
| Software ID: | |
| Software Version: |
Attach to Form 990 or 990-EZ.| Identifier | Return Reference | Explanation |
|---|---|---|
| VOLUNTEERS | Form 990, Part I, Question 6 | Volunteers serve in a variety of ways but the greatest numbers of volunteers assist with the Susan G. Komen 3 Day series. Program Service Accomplishments Form 990, Part III, Lines Nancy G. Brinker promised her dying sister, Suzy, she would do everything in her power to end breast cancer. Susan G. Komen(Komen) works to end breast cancer in the U.S. and throughout the world by investing in breast cancer research and community outreach programs; providing funding to help low-income and uninsured women get screened and get treatment; advocating for cancer research and outreach programs; and working globally in more than 30 countries. A - Research and Training Komen has contributed to major advances in breast cancer research over the past 30 years. Komen's Research and Training Grant Program is designed to advance the translation of research discoveries into new ways to diagnose, treat, and prevent breast cancer, leading to a reduction of breast cancer incidence and mortality within the next decade. To ensure maximum impact for its research dollars, Komen is guided by a Scientific Advisory Board, a group of internationally recognized doctors, scientists and advocates, and consults with the Komen Scholars, a group comprised of 70 scientists and advocates. Komen awards grants to individual scientists, research teams, and organizations around the world through competitive review processes that ensure maximum impact for our research dollars. In fiscal year 2013, Komen awarded 124 grants through its Research and Training Grants Program to support research and training in the United States and other countries, including Australia, Belgium, Canada, England, France, Italy, Spain, and Switzerland. The following Request-for-Applications-driven grant opportunities were offered by Komen during fiscal year 2013: Challenge Grants: Breast Cancer and the Environment Grants to address key research needs in the field of environmental contributions to breast cancer risk. Komen and its Scientific Advisory Board requested that the Institute of Medicine (IOM) review the current evidence on environmental risk factors for breast cancer, consider gene-environment interactions in breast cancer, explore evidence-based actions that might reduce the risk of breast cancer, and recommend research needed in these areas. At the conclusion of its grant, IOM issued 13 recommendations for further research, of which the following three have been chosen by the Komen Scientific Advisory Board as the subject of Challenge Grants awarded in fiscal year 2013: *Studies of Occupational Cohorts and Other Highly Exposed Populations *New Exposure Assessment Tools *Minimizing Exposure to Ionizing Radiation Investigator Initiated Research: Grants to explore new ideas and approaches with significant potential to lead to reductions in breast cancer mortality and/or incidence within the decade, with a focus on the following: *Prevention/Early Detection: New Strategies for Early Detection *Novel Therapeutics and/or Resistance: Therapeutic Implications of Tumor Genomics *Biology of Breast Cancer: Implications of the Immune System in Breast Cancer Biology *Disparities in Breast Cancer Outcomes: Outcomes of Specific Populations after Diagnosis Career Catalyst Research: Grants to fill a critical gap in support and stimulate the transition from training to independence among promising cancer investigators. Komens research investment through the above grant mechanisms will support projects including, but not limited to, the following goals: *Identify the true drivers of resistance in HER2+ breast cancer, which can subsequently be targeted in combination therapy, thus circumventing resistance. *Identify molecular markers to predict and track response to treatment targeted to ER+ breast cancer, and understand pathways of resistance that can inform and change the treatment regimen. *Seek to develop new molecular markers for progression from in situ to invasive breast cancer. *Use improved digital imaging to better capture breast calcifications and reduce secondary screenings. *Seek to understand how breast cancer escapes the immune system. *Develop a vaccine to treat metastatic breast cancer. *Understand how genes involved in normal breast development are also involved in breast cancer progression. *Develop new treatments for triple negative and other aggressive, treatment-resistant disease. *Identify determinants of survival that are modifiable, to save women from sub-Saharan Africa of death from breast cancer. *Seek to improve outcomes among minority and low-income women through stress and fatigue management. Opportunity Grants / Sponsored Programs and Partnership Grants: Grants to support special research projects, programs, and collaborations that leverage research and community resources to facilitate the development of the infrastructure, tools, and other means to accelerate the translation of scientific discoveries from bench to bedside to curbside. Examples of Opportunity Grants committed in fiscal year 2013 include: *The Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center ("Komen Tissue Bank," "Tissue Bank" or "KTB"), a biorepository of whole blood, DNA, serum, plasma, frozen human breast, formalin-fixed, paraffin-embedded breast tissue, and cell lines derived from the breast tissue, and the first and only biorepository of normal breast tissue in the world. The mission of the Komen Tissue Bank is to facilitate progress in breast cancer research by providing researchers across the globe with richly annotated biospecimens of the highest quality and the experimental data derived from these specimens. The Komen Tissue Bank, a model for biorepositories, represents a major change in research of breast biology and will hopefully have a huge impact in our community and the world. It has the potential to help identify people at risk for breast cancer as well as those not at risk for the development of the disease. *The International Program on Male Breast Cancer (International Registration and Biologic Characterization Program) organized by the European Organization for Research and Treatment of Cancer (EORTC), the Breast International Group (BIG), and the North American Breast Cancer Groups (NABCG, former TBCI) aims to better characterize the clinical features, biology, and outcomes for men diagnosed with breast cancer. Examples of Sponsored Programs and Partnership Grants committed in fiscal year 2013 include: *Support for the Accelerating Anti-Cancer Drug Development Workshop, which is designed for scientists and consumer advocates with clinical trial experience who have an interest in new approaches to developing or enhancing agents or combinations of agents for the diagnosis, treatment or prevention of cancer. This groundbreaking Workshop is designed to bring together leaders in clinical and translational cancer research from academia, industry, NCI and FDA to assist investigators in understanding and improving the process of cancer drug development. The goal is to expedite the development and validation processes for new anticancer and cancer prevention agents so they can be made available to patients at an accelerated rate. *Support for the Friends of Cancer Research 2013 Conference on Clinical Cancer Research, which focuses on addressing critical issues in the development of new oncology drugs. Friends of Cancer Research and the Engelberg Center for Health Care Reform at Brookings will co-host the sixth annual Conference on Clinical Cancer Research. This annual conference brings together leaders in cancer drug development from federal health and regulatory agencies, academic research, and the private sector for focused discussions on key issues surrounding the development and regulation of cancer drugs and therapies. |
| B - Education | Komen is a trusted source of breast cancer information for people all over the world and is instrumental in connecting people with the resources they need in their fight against breast cancer. Our award-winning website, www.komen.org, provides safe, accurate, comprehensive, and unbiased information about breast cancer based upon scientific evidence, as well as information about our research programs, community programs, volunteer opportunities, and events. The "Understanding Breast Cancer" section of the website, co-developed with Harvard Medical School faculty and Dana-Farber/Brigham and Women's Cancer Center staff, received over 3.3 million visits during fiscal year 2013. Komen also produces evidence-based, easy-to-read educational materials. Komen and its Affiliates distributed over 5 million educational materials in fiscal year 2013. Examples of Komen educational materials include the following: - Breast Self-Awareness cards in 21 languages and for 22 specific audiences - Breast cancer awareness and breast cancer specific brochures and fact sheets - Booklets with support information for survivors and co-survivors Komen's trained and caring breast care helpline staff (1-877 GO KOMEN, 1-877-465-6636) provide answers to questions, local resources, and moral support. Last fiscal year, the Komen breast cancer helpline responded to over 1,213,000 calls and 1,000,100 emails. While older African American women are less likely to be diagnosed with breast cancer than Caucasian women, they are more likely to die from the disease at every age. Komen's Circle of Promise program engages African American women, and black women around the world, in the fight against breast cancer. As of the end of fiscal year 2013, a total of 100,000 ambassadors had been recruited to do the following: - Mobilize the community to ensure that women everywhere have access to the care they need; - Empower women to make a promise to reclaim their lives, their health, and to be strong advocates in their communities, and - Dispel myths in these communities that prevent women from getting treatment for breast cancer. I AM THE CURE is an educational program that teaches simple, action-oriented, breast cancer information to participants in the Komen Race for the Cure series. Last year, nearly 1.5 million people participated in a Race for the Cure event. A formal evaluation showed that 82% of participants recalled the message that early detection is the key to survival. Cancer kills more people, worldwide, than TB, HIV/AIDS and malaria combined. Komen is waging the global fight against breast cancer by building and strengthening grassroots programs through networking, training, capacity building and financial support. In fiscal year 2013, 168 breast cancer advocates in three countries (Brazil, Costa Rica, and Mexico) were trained on the Community Educators program and Course for the Cure curricula. The Community Educators program is a theory-based trainer curriculum targeted for education program planners and Course for the Cure is a series of capacity building modules based on Komen's best practices and experience aimed at helping local non-government organizations increase their reach and impact. In Partnership with the Caterpillar Foundation, Komen funded programs in Brazil, Panama, and Mexico that reached an estimated 3.3 million people through awareness campaigns and trained 1,681 community health workers and medical providers, while also reaching 24,616 community members through breast self awareness and breast cancer through the end of fiscal year 2013. Also, since inception of the program, these grants provided for the distribution of 232,447 educational materials, 2,678 clinical breast exams, 5,419 mammogram referrals, and 427 mammograms. Komen also awarded grants for outreach programs in Bosnia and Herzegovina, Colombia, Germany, Hungary, Kenya, Mexico, Peru, Russia, Rwanda, The Bahamas, The United Arab Emirates, and Zambia. Furthermore, Komen awarded grants aimed at 1) conducting a comparative baseline needs assessment for breast cancer awareness and management in select countries in the Middle East and North Africa and 2) developing a Global Project Database on women's cancers and conducting a full scale effort to develop a Global Pink Paper/Report, a complimentary body of work focused specifically on women's cancers. C - Screening Getting regular screening tests, along with treatment if diagnosed, lowers the risk of dying from breast cancer. Screening tests can find breast cancer early, when survival is highest. Komen supports free and low-cost mammogram programs in communities for women without health insurance or those with high co-pays and deductibles that make getting a mammogram too costly. In 2013, Komen awarded $1.5 million for seven new community grants to reach low-income, minority and uninsured women who fall through the healthcare gaps in the Washington, D.C. Metro area, where death rates from breast cancer continue to rank above national averages. The new Komen grants bring to 18 the number of Komen-funded programs in the D.C. area that strive to improve access and services to women facing breast cancer, representing a total in active grant funding of $7.3 million. All seven new grants in the Washington, D.C. Metro area focus on addressing barriers to care caused by the region's fragmented heath care system and lack of care coordination among vulnerable patients. All new grantees were required to form partnerships among providers in the region that establish a framework to ensure that patients can be easily and efficiently referred and "navigated" from screening all the way through to survivorship-with particular emphasis on removing obstacles to transportation and work obligations, wait times, and financial assistance. In addition, several of the programs focus on patient education, including targeted breast health awareness outreach in a culturally sensitive manner that develops a better understanding of the importance of screening, the effectiveness of modern treatments and survivorship. Through Komen's National Vulnerable Populations Grants Program, Komen funds large-scale community grants that seek to improve quality of care, care coordination, and address unique barriers to breast care for disparate populations. Since the initiation of these grants in 2008, Komen has invested over $9 million in programs that aim to eliminate disparities in breast cancer mortality. Projects funded in fiscal year 2013 through Komen's National Vulnerable Population Grants Program are focused on quality and systems improvement. Grantees will develop more effective and efficient processes for screening, referral, diagnosis, treatment, follow-up and survivorship by developing and implementing systems and process change to reduce breast cancer disparities among vulnerable populations. The Vulnerable Populations Grant Program supports projects that: *Implement quality improvement and process improvement strategies to eliminate disparities in screening, care and/or treatment across multiple communities, geographic regions, and/or populations; *Propose implementation of models that seek to improve processes and systems using quality improvement strategies; and *Demonstrate collaboration among stakeholders to develop systems that increase access and utilization of breast health services to all women throughout the breast cancer continuum of care. | |
| D - Treatment | Many people do not get the breast cancer treatment they need, and as a result, they are less likely to survive. For this reason, Komen supports two treatment assistance programs managed by CancerCare and the Patient Advocate Foundation which aim to connect people with local resources, psychosocial support, and provide critical financial assistance. Both programs, collectively, provide supplementary direct financial help to over 10,000 breast cancer patients for medical co-payments, oral chemotherapy, and other vital care that is related to treatment. In 2013, Komen awarded a $500,000 grant to CancerCare to support the Linking A.R.M.S.(TM) (Assistance & Resources Made Simple) program. Linking A.R.M.S.(TM) is a program dedicated to providing financial assistance, education and support services to low-income, under- or uninsured breast cancer survivors. Funding for Linking A.R.M.S.(TM) provides direct financial assistance to more than 2,100 breast cancer survivors for treatment-related expenses including pain and anti-nausea medication, lymphedema care, oral chemotherapy, durable medical equipment, childcare, and transportation to and from treatment. CancerCare also provides counseling and other support services that enable breast cancer patients to make informed treatment decisions, cope with the emotional effects of the disease, and experience an improved quality of life. In 2012 Komen awarded a $1,500,000, two-year grant to the Patient Advocate Foundation (PAF), a national non-profit organization that assists patients needing help with health-related financial issues. Komen supports PAF's Co-Pay Relief (CPR) program. The CPR program provides direct financial assistance for pharmaceutical co-payments to insured patients with breast cancer, lung cancer and prostate cancer. Komen's funding, along with other key partners, touched more than 10,000 breast cancer patients served through the program over the past two years. For more information about any of the accomplishments described here or to learn more about Susan G. Komen for the Cure, visit www.komen.org or call 1-877 GO KOMEN (1-877-465-6636). | |
| Significant Change to governing documents | Form 990, Part VI, Question 4 | At a meeting of the Board of Directors on May 31, 2012, the Board approved an amendment to the Amended and Restated Bylaws (of June 4, 2010) adding a second, Class III director, increasing the total number of members of the Board of Directors to 10. On November 7, 2012, the Board of Directors approved an amendment to the Bylaws adding a new Board Officer position of Vice Chair. Describe the Process used by Management &/or Governing Body to Review 990 Form 990, Part VI, Question 11b Management prepares the materials for the Form 990, with the assistance and review by external accountants. Senior levels of management review and comment on the final draft of the Form 990 for presentation to the audit committee of the board of directors. The audit committee of the Board of the Directors reviews and approves the Form 990 prior to being filed. Thereafter, each member of the Board of Directors receives an electronic copy of the Form 990 via email prior to the form being filed. Description of Process to Monitor Transactions for Conflicts of Interest Form 990, Part VI, Question 12c Komen produces an annual survey requiring all employees, board members, committee members, and advisory boards to inform on conflicts. Any conflicts are then reviewed by management and the audit committee and appropriate measures are taken. In addition, those same people have the obligation to update the conflict of interest statements during the year. Offices & Positions for Which Process was Used, & Year Process was Begun Form 990, Part VI, Questions 15a and 15b The Compensation Committee of the Board of Directors assists the Board of Komen in overseeing compensation policies and practices. Responsibilities include oversight of the compensation of the President/ Chief Executive Officer, the range of compensation levels for the organization's other officers, disqualified persons, and other employees, granting the CEO authority to determine actual compensation levels within an approved range, and incentive/bonus compensation programs. The current policy was adopted in 2010. A formal Compensation Policy governs pay practices. Periodically, all positions in the organization are reviewed against external market data, engaging independent experts to conduct the benchmarking process. Compensation is then based upon comparable market rates of pay with consideration for internal equity and the financial position of the organization. For the CEO and officers of the organization, external benchmarking was conducted again this fiscal year to ensure market alignment. Salary increases, promotions or other forms of compensation are provided without regard to race, color, religion, gender, national origin, disability, veteran status or sexual orientation. Avail of Gov Docs, Conflict of Interest Policy, & Fin Stmts to Gen Public Form 990, Part VI, Question 19 Komen's financial statements, conflict of interest policy and the 990 are publicly available on our website. The Articles of Incorporation are available from the Texas Secretary of State and other governing documents are made available as required by state law. Form 1023 is not online but available to the public upon request. ADDITIONAL DETAIL ON EVENT PRODUCTION EXPENSES INCLUDED ON OTHER EXP LINE Form 990, Part IX, Line 24 The Susan G. Komen Breast Cancer Foundation, Inc. purchases all T-Shirts for the 136 Races held by the Komen Affiliates during the year. Part X Balance sheet, Line 19 Deferred Revenue from the prior year was reclassified to properly represent the balance. Reconciliation of Net Assets : Part XI, Line 6 In Kind Services - Revenues 10,930,757 In Kind Services - Expenses (11,271,796) Rounding 1 ------------ Total Donated services (341,038) Reconciliation of Net Assets : Part XI, Line 9 Rescinded Grants 3,652,555 |
| Software ID: | |
| Software Version: |